Zogenix, Inc. (ZGNX): Price and Financial Metrics


Zogenix, Inc. (ZGNX): $26.68

0.42 (+1.60%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ZGNX Stock Price Chart Interactive Chart >

Price chart for ZGNX

ZGNX Price/Volume Stats

Current price $26.68 52-week high $26.90
Prev. close $26.26 52-week low $11.03
Day low $26.51 Volume 11,252,300
Day high $26.90 Avg. volume 3,764,363
50-day MA $22.56 Dividend yield N/A
200-day MA $17.33 Market Cap 1.50B

Zogenix, Inc. (ZGNX) Company Bio


Zogenix develops and commercializes therapies for the treatment of central nervous system disorders. The company was founded in 2006 and is based in San Diego, California.


ZGNX Latest News Stream


Event/Time News Detail
Loading, please wait...

ZGNX Latest Social Stream


Loading social stream, please wait...

View Full ZGNX Social Stream

Latest ZGNX News From Around the Web

Below are the latest news stories about Zogenix Inc that investors may wish to consider to help them evaluate ZGNX as an investment opportunity.

Analysts Estimate Envestnet (ENV) to Report a Decline in Earnings: What to Look Out for

Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Entrepreneur.com | February 17, 2022

Zogenix (ZGNX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

Zogenix Supports New No-Cost Genetic Testing Program with United Mitochondrial Disease Foundation to Improve Diagnosis of Mitochondrial Diseases

Symptoms of mitochondrial diseases, such as Thymidine Kinase 2 deficiency (TK2d), can vary widely and mimic other rare and common diseases, making diagnosis challenging 1,2,3Genetic testing offers a quicker, confirmatory path to diagnosis, enabling more accurate care and participation in available clinical trials 1,2,3An estimated 1 in 5,000 individuals has a genetic mitochondrial disease 4 EMERYVILLE, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical c

Yahoo | February 15, 2022

Why Zogenix Flew Higher Before Leveling Off This Week

Zogenix (NASDAQ: ZGNX) stock is having the ride of its life this week -- perhaps for the last time in its history. The biotech announced Wednesday it agreed to be acquired by Belgium-based pharmaceutical company UCB (OTC: UCBJF). The company's share price quickly rocketed higher, but it's basically stayed at the enhanced level.

Yahoo | January 21, 2022

Biotech Stock Roundup: ZGNX's Acquisition News, REGN, BLUE's Updates & More

Regulatory and other pipeline updates from Zogenix (ZGNX) and Regeneron (REGN) are among a few key highlights from the biotech sector during the past week.

Yahoo | January 20, 2022

Read More 'ZGNX' Stories Here

ZGNX Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 125.15%
3-year -42.98%
5-year -22.72%
YTD 64.18%
2021 -18.71%
2020 -61.65%
2019 42.98%
2018 -8.96%
2017 229.63%

Continue Researching ZGNX

Want to see what other sources are saying about Zogenix Inc's financials and stock price? Try the links below:

Zogenix Inc (ZGNX) Stock Price | Nasdaq
Zogenix Inc (ZGNX) Stock Quote, History and News - Yahoo Finance
Zogenix Inc (ZGNX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.847 seconds.